The pharma giant Pfizer announced to continue investigating the data manipulations committed by their former cancer researcher Min-Jean Yin, retractions of two more publications were requested and yet another paper’s fate is being currently decided. Again it is about studies of pharmacological inhibitors of cancer molecular pathways which Yin’s former lab at the Pfizer California research site has faked. These two retraction requests come is addition to 5 Yin retractions which Pfizer already announced on my site in October 2016 and which meanwhile happened. The PubPeer-listed evidence was first presented on my site in May 2016. Back then, the reader of my site, who posted that evidence of duplicated western blots on PubPeer and alerted me to it, preferred to remain unnamed. Now however, she agreed to be named: it was the microbiologist, image integrity specialist and host of the successful public outreach blog Microbiome Digest, Elisabeth Bik. She now forwarded to me this message: Continue reading “Pfizer announces more retractions for sacked lab head Min-Jean Yin, whistleblower revealed”
Arthur Caplan, internationally respected professor of bioethics and director of the Division of Medical Ethics at the New York University, requested publicly retractions of the bioethics reviews on regenerative medicine he co-authored with the scandal surgeon Paolo Macchiarini. Caplan notified the journals with his retraction requests, but said to have received no response from them yet. Not only this: Caplan calls for all works of Macchiarini to be retracted.
Macchiarini is now an international pariah, he recently again lost his job, this time with the Kazan Federal University in Russia (see my report). His publications are under investigation at his former workplace the Karolinska Institutet in Stockholm (where he was previously sacked), the Swedish state announced to soon charge him with manslaughter, due to 3 lethal plastic trachea transplants he performed at Karolinska. Continue reading “Bioethicist Arthur Caplan calls for retraction of all Macchiarini papers”
Paolo Macchiarini is leaving Russia, his research and surgery stint there is over. The fallen star surgeon was able to find a professorship with the Federal University of Kazan (KFU), after his plastic trachea transplants at the Kuban State Medical University in Krasnodar left 3 patients dead, and one with a lucky escape (see details here). His new research focus was on artificial oesophagus, which he apparently already started to test on hapless baboons. In March 2017, the Russian state decided that Macchiarini’s federal grant on oesophagus research will not be renewed, the Kazan University announced in regard to their professor’s further employment to follow the instructions from the Russian Science Foundation. The professorship contract expires by December 2017. On April 20th, Kazan University made the official decision to shut down Macchiarini’s research programme. A Russian opposition party, Yabloko, demanded of the Ministry for Research and Education to investigate Macchiarini’s Megagrant funding and the use of that money, especially in view of the fact that no final report was published. All this information was revealed by the Russian health and medicine journalist Alla Astakhova on her website. Continue reading “Macchiarini leaves Russia: federal grant denied and Kazan lab shut down”
Academic research is dependent on funding, and funding agencies, both public and charity ones, play a crucial gatekeeper function in deciding who will go on to continue researching or even working in science, and who will not. With great power comes great responsibility. Unfortunately, funders traditionally end up serving the interests of select elite scientists by confusing the needs of those with the greater good of science as such. Money is dumped on the biggest pile, either to established star researchers or to their privileged academic scions. In this zero-sum game of science funding, many early career researchers see their grant applications rejected and are forced out of academia. The logic seems to be that this research proletariat would have spent it on booze and candy anyway, while the high elite will be investing it wisely to produce great science. Or whatever the funders, advised by that very elite, perceive to be great science. The guest post below by Shravan Vasishth, professor for psycholinguistics and neurolinguistics at the University of Potsdam, Germany, tells of a peer reviewer experience of his when it hit against such attitude from the most prestigious EU research funder, the European Research Council (ERC).
Trachea is a very difficult organ to transplant, because its blood supply happens through many tiny blood vessels and it is practically impossible to connect them all (same is true also for the oesophagus). An organ transplanted without blood supply will die, and this is where the regenerative medicine of Paolo Macchiarini and Martin Birchall comes in: a treatment with stem cells and growth factors will somehow magically ensure quick vascularization and bring the dead tissue to life. There is no independent evidence for this, and most patients died as the consequence or became dangerously ill when their new tracheas, made from plastic or from dead, decellurised cadaveric organs predictably failed. One boy has survived: Ciaran Lynch. His current clinical state is not too rosy, even by Birchall’s own admittance, but nevertheless the sole fact that Ciaran (unlike almost all other trachea transplant patients) is alive, sufficed for Birchall to have one or two more patients operated (both dead) and to push through a clinical trial in UK with a much larger follow-up trial EU-wide. The difference though: that boy never had much choice anyway, since he had no real trachea in the first place. He received very early on a pickled trachea homograft from dead human donor tissue which functioned very well for many years, but at some point urgently needed replacement in order to save his life. Now Birchall however wishes to remove the live airways of stable patients outside any life danger, who suffer from tracheal stenosis, and replace them with his regenerated dead ones (see this report). Noone seems to wonder why these tracheas are to be prepared in a radically different way from that of the sole success, Ciaran Lynch: Birchall’s bioreactor vs so-called “bionic” method of Macchiarini.
Today I stood my second injunction trial (previous here), and once again, the evidence was irrelevant. Today’s trial of Philipp Jungebluth against myself in the Berlin regional court was set for 30 minutes and this is also how long it took. The reason: the judge (and two co-judges) already made up their decision to uphold Jungebluth’s injunction against me (see story here and here), regardless of all evidence from my side about this doctor’s past. They were perfectly free to do so, because it was a speed trial, where (in theory) I was supposed to get my chance to finally defend myself after the very same judge passed that injunction without my prior knowledge or involvement, based on the claims submitted by Jungebluth. Such is the German law on press freedom, take it or leave the country. Also now, I didn’t get to say much, while Jungebluth and his lawyer were welcomed to explain their case to the court once again. My lawyer and I hardly got a chance to squeeze a word in. Continue reading “Judge in Jungebluth trial announces to uphold his injunction, dismisses all evidence”
The hammer has fallen. The lab of misconduct-tainted plant scientist Patrice Dunoyer at the CNRS Institut de Biologie Moléculaire des Plantes (IBMP) in Strasbourg, France, has been closed with a 48 hour notice, following the decision of the institute’s director Laurence Maréchal-Drouard. The (now former) lab members were informed by general mailing list announcement; the reasons for closure were officially “not related to integrity concerns”. The only good news for Dunoyer is that he is tenured, and cannot be sacked for his previous research misconduct, because CNRS already punished him for it with a whole one-month suspension.